profit from every $100 of sales.
$0$100
Carlsmed
$17.12-1.04% today
+34.6% in 1 year
1-year low $8.831-year high $18.60
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Carlsmed sold, what it kept, and what it did with the cash.
Sales went from $13.8 million in 2023 to $50.5 million in 2025, with -$29.6 million of profit last year.
SalesProfit
Carlsmed vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Carlsmed | No profit yet | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads Carlsmed's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 14 | 27 | 51 | |
| 10 | 20 | 38 | |
| -19 | -24 | -31 | |
| -18 | -23 | -28 | |
| -19 | -24 | -30 | |
| -4.25 | -6.11 | -2.12 | |
| 71.9% | 73.8% | 75.3% | |
| -134.9% | -88.8% | -60.5% | |
| -137.2% | -89.3% | -58.7% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 14 | 52 | 130 |
| Cash | 7 | 40 | 86 |
| Total debt | 11 | 17 | 17 |
| Total liabilities | 60 | 122 | 31 |
| -46 | -71 | 99 | |
| 4 | 4 | 14 | |
| – | – | -19.2% | |
| 41.0% | 34.3% | -30.0% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -17 | -25 | -29 | |
| 0 | 0 | 1 | |
| -18 | -26 | -30 | |
| Dividends paid | – | – | – |
| – | – | – | |
| 0 | 0 | 2 |
Valuation
- –
- –
- –
- 3.2×
- 9.3×
- –
- –
- -6.5%
- -6.3%
- 0.0%
Profitability
- 75.3%
- -60.5%
- -58.7%
- -67.0%
- -19.8%
- 24.6%
- -61.8%
- -27.9%
- -20.0%
- 33.7%
Growth
- +91.5%
- –
- −15.5%
- –
- +78.9%
Financial health
- -2.4×
- 0.19
- 14.5%
- -19.5×
- 11.88
- 11.67
- 0.48
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 22%of 946
Bottom 6%of 871
Top 7%of 867
Bottom 16%of 986
What analysts expect
- Average price target
- $20.67
- Range
- $18.00 – $24.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.32 | -0.43 | +25.6% |
| Feb 25, 2026 | -0.32 | -0.43 | +25.6% |
| Nov 6, 2025 | -0.40 | -0.45 | +11.1% |
| Aug 28, 2025 | -1.47 | -1.52 | +3.3% |
News
Carl Icahn’s CVR Energy reportedly nears $4B deal to acquire Marathon refineriesSeeking Alpha · Nov 3, 2026GURU Organic Energy announces CEO succession as Carl Goyette steps down; Tyler Ricks named Executive ChairSeeking Alpha · Sep 10, 2026Carl Icahn lowers his stake in JetBlue below the reporting thresholdSeeking Alpha · Aug 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
46No pass
Benjamin Graham
41No pass
Philip Fisher
61Pass
Peter Lynch
72Pass
Joel Greenblatt
2No pass
Charlie Munger
54No pass
Terry Smith
58No pass
Questions about Carlsmed
Is Carlsmed a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Carlsmed AI analysis
What does Carlsmed do?
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. It is in Medical - Healthcare Information Services.
Does Carlsmed pay a dividend?
No. Carlsmed does not pay a dividend at the moment.
Is Carlsmed stock halal?
Yes. Carlsmed passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has Carlsmed stock done over the past year?
Up 34.6% over the past twelve months, to $17.12. It traded between $8.83 and $18.60 and is 8.0% below its high.
Who are Carlsmed's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Carlsmed's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.